bioMmune Technologies Inc. | |
Stock Exchange | Other OTC |
EPS |
$0.06 |
Market Cap |
$6.31 M |
Shares Outstanding |
52.02 M |
Public Float |
- |
Address |
400 Burrard Street Vancouver British Columbia V6C 3A6 Canada |
Employees | - |
Website | http://www.pascalbiosciences.com |
Updated | 07/08/2019 |
Pascal Biosciences Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: Major Histocompatibility Complex I (MHC I), CD74 and Calcium Channel Blockers. The MHC I technology is a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells where the fragments are then exposed to the immune system's T cells. |